Insight

Adding 6 months of androgen deprivation therapy to post-operative radiotherapy for prostate cancer

Photo of Chris Parker from royalmarsden.nhs.uk

Sep 7, 2024, 10:22

Adding 6 months of androgen deprivation therapy to post-operative radiotherapy for prostate cancer

European Society for Radiotherapy and Oncology (ESTRO) shared a post on LinkedIn about a recent paper by Chris Parker et al. published in The Lancet.

“Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial”

Authors: Chris Parker, Noel Clarke, Adrian Cook, Mahesh Parmar, Matthew Sydes et al.

“Adding 6 months of androgen deprivation therapy to post-operative radiotherapy for prostate cancer, published in The Lancet.

Read it before your patients.”

Adding 6 months of androgen deprivation therapy to post-operative radiotherapy for prostate cancer

Source: ESTRO/LinkedIn

Adrian Cook ADT androgen deprivation therapy cancer Chris Parker ESTRO European SocieTy for Radiotherapy and Oncology Mahesh Parmar Matthew Sydes Noel Clarke OncoDaily Oncology prostate cancer RADICALS-HD The Lancet

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage